Market closed

Altimmune/$ALT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Altimmune

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Ticker

$ALT
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Gaithersburg, United States

Employees

59
Website
altimmune.com

Altimmune Metrics

BasicAdvanced
$482M
-
-$1.53
0.07
-

$482M

0.07

$14.84

$5.28

3.1M

16.874

16.522

1.095

1.329

-9,951.00%

-39.56%

-72.96%

8,851.175

3.62

3.62

-5.886

-81.36%

-1.05%

-75.29%

-10.25%

What the Analysts think about Altimmune

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Altimmune stock.

Altimmune Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Altimmune Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Altimmune News

AllArticlesVideos
Altimmune Could Find A Partner For Its Phase 3 Exercise

Altimmune Could Find A Partner For Its Phase 3 Exercise

Seeking Alpha·2 weeks ago
Altimmune Added to Nasdaq Biotechnology Index

Altimmune Added to Nasdaq Biotechnology Index

GlobeNewsWire·4 weeks ago
Altimmune 2025: Redefining Obesity And MASH Treatment

Altimmune 2025: Redefining Obesity And MASH Treatment

Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALT

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Altimmune stock?

Altimmune (ALT) has a market cap of $482M as of January 15, 2025.

What is the P/E ratio for Altimmune stock?

The price to earnings (P/E) ratio for Altimmune (ALT) stock is 0 as of January 15, 2025.

Does Altimmune stock pay dividends?

No, Altimmune (ALT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Altimmune dividend payment date?

Altimmune (ALT) stock does not pay dividends to its shareholders.

What is the beta indicator for Altimmune?

Altimmune (ALT) has a beta rating of 0.07. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.